TABLE 1.
Demographics and baseline characteristics of study participants (safety population a )
| Demographic | Part A b total (N = 23) | Part C c | Part C total (N = 25) | |
|---|---|---|---|---|
| Placebo (N = 11) | GSK3358699 10 mg QD (N = 14) | |||
| Age, mean (range), y | 31 (18‐45) | 39 (29‐51) | 39 (20‐55) | 39 (20‐55) |
| Male, n (%) | 23 (100) | 11 (100) | 14 (100) | 25 (100) |
| BMI, mean (SD), kg/m2 | 25 (3) | 25 (3) d | 25 (3) | 25 (3) |
| Height, mean (SD), cm | 176 (6) | 181 (9) d | 175 (6) | 177 (8) |
| Weight, mean (SD), kg | 79 (12) | 81 (14) d | 77 (14) | 79 (14) |
| Ethnicity, n (%) | ||||
| Hispanic or Latino | 2 (9) | 3 (27) | 0 | 3 (12) |
| Not Hispanic or Latino | 21 (91) | 8 (73) | 14 (100) | 22 (88) |
| Race, n (%) | ||||
| Black or African American | 1 (4) | 1 (9) | 0 | 1 (4) |
| White | 21 (91) | 10 (91) | 14 (100) | 24 (96) |
| Multiple | 1 (4) | 0 | 0 | 0 |
Abbreviations: BMI, body mass index; QD, once daily; SD, standard deviation.
a
The safety population consisted of all randomized participants who received at least one dose of study treatment.
b
Part A was a single ascending‐dose crossover study in two interlocking cohorts. Each participant received a maximum of two single ascending oral doses of GSK3358699 (1, 3, 10, 20, 40 or 30 mg) and one dose of placebo.
c
In part C, participants received 10 mg of GSK3358699 or placebo daily for up to 14 days.
d
n = 10 for these parameters.